Dr. Michael Rosenberg to present a session on implementing successful adaptive programs for dramatically shorter, more efficient development timelines
Durham, NC: June 9, 2009
Drug Information Association 45th Annual MeetingHealth Decisions (www.healthdec.com, Booth 1447) announces that President and CEO Michael Rosenberg, MD, MPH will lead a paneled session June 23 at the DIA Annual Meeting in San Diego. The Practice of Adaptive Research will focus on the pragmatic aspects of planning and managing complete adaptive programs – including the balance between mid-trial adjustments to both design and operations; the technology platform required to support these programs; and the broader implications of adaptive decision-making to the global pharmaceutical market.
According to Rosenberg, rising development costs, reimbursement pressures, and the global economic environment make the time- and cost-saving benefits of adaptive clinical research more important than ever.
The Practice of Adaptive Research will include the following presentations from industry experts:
“Operational Adaptations: Running Tighter, Faster Studies,” presented by Mike Ford, director of data management at Health Decisions
“Drug Supply in Adaptive Studies,” presented Michael Krams, MD, vice president of Adaptive Trials and Applied Program Strategies at Wyeth
“Statistical Issues,” presented by Roger J. Lewis, MD, PhD, Professor of Medicine, Department of Emergency Medicine at Harbor UCLA Medical Center
“Financial Benefits of Adaptive,” presented by Michael Rosenberg, MD, MPH, president and CEO of Health Decisions
The Practice of Adaptive Research is part of the R&D Strategy (RD) track, and takes place June 23 from 10:00 – 11:30 a.m. PST in Room 14B. To view the abstract, please click here.
For sales and marketing information, please contact David Cerny, Director of Business Development, West, by email at firstname.lastname@example.org or by phone at +1.919.967.1111 x111.
For media information, please contact Betsy Carr, Marketing Manager at email@example.com.
About the DIA Annual Meeting
Hosted by the Drug Information Association, the DIA 45th Annual Meeting takes place June 21 – 25, 2009 at the San Diego Convention Center, California. The DIA Annual Meeting is the biopharmaceutical industry’s largest, longest running, best-value, global, multidisciplinary event. The 2009 program offers learning opportunities for everyone and features the biggest names from industry, regulatory, and academia. To learn more, click here.
About the Drug Information Association (DIA)
DIA serves more than 30,000 biopharmaceutical professionals from industry, academia, and regulatory agencies worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.
About Health Decisions
Health Decisions (www.healthdec.com), a global clinical research organization (CRO), leads the industry in trial efficiency. Through integrated technology and agile clinical development methods that apply adaptive principles to both trial design and operations, Health Decisions provides sponsors unprecedented transparency and control and produces results 10-40 percent faster than traditional approaches.
Health Decisions is headquartered in Durham, NC, with over twenty years of drug development experience in setting new standards of speed and accuracy for pharmaceutical, biotech and medical device companies in Phase I-IV trials across all major therapy areas. For more information, please visit the company’s website at www.healthdec.com.
“Applying adaptive principles to study design as well as day-to-day operations presents an immediate promise of a dramatically faster, more efficient development pathway. We can eliminate poor candidates earlier, get good products to market faster, and make it financially attractive to focus on smaller, more individualized populations, including individualized therapies.”
President and CEO